Molecular Biology Reports

, Volume 41, Issue 10, pp 7023–7029 | Cite as

Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population

  • Gilberto Vargas-Alarcón
  • Julián Ramírez-Bello
  • Aurora de la Peña
  • Beatriz Calderón-Cruz
  • Marco Antonio Peña-Duque
  • Marco Antonio Martínez-Ríos
  • Silvestre Ramírez-Fuentes
  • Oscar Pérez-Méndez
  • José Manuel Fragoso


The aim of the present study was to establish the gene frequency of six polymorphisms of the ABCB1, CYP3A5, CYP2C19, and P2RY12 genes in a population resident of Mexico City. The proteins encoded by these genes have been associated with the absorption, and biotransformation of clopidogrel. The ABCB1 T3435C, CYP3A5 V3* A6986G, P2RY12 G52T, P2RY12 C34T, CYP2C19 V2* and V3* (positions G681A and G636A, respectively), polymorphisms were analyzed by 5′ exonuclease TaqMan genotyping assays in a group of 269 healthy unrelated Mexican Mestizo individuals. The CYP2C19 V3* G636A polymorphism was not detected in the Mexican Mestizos population. However, the studied population presented significant differences (P < 0.05) in the distribution of the T3435C, A6986G, G681A, G52T and C34T polymorphisms when compared to reported frequencies of Amerindian of South America, Caucasian, Asian, and African populations. In summary, the distribution of the ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms distinguishes to the Mexican Mestizos population from other ethnic groups.


Genetic variability Polymorphism Mexican Mestizos population Real time PCR analysis 



ATP-binding cassette, sub-family B1 (P-glycoprotein)


Cytochrome P 450, family 3, subfamily A, polypeptide 5


Cytochrome P 450, family 2, subfamily C, polypeptide 19


Purinergic receptor P2Y, G-protein coupled, 12



This work was supported in part by grants from the Consejo Nacional de Ciencia y Tecnología and Fundación Gonzalo Rio Arronte, Mexico City, Mexico. The authors are grateful to the study participants. Institutional Review Board approval was obtained for all sample collection.

Conflict of interest

The authors report no conflicts of interest.


  1. 1.
    Anderson JL, Adams CD, Antman EM et al (2008) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116:e148–e304 [Erratum, Circulation. 117:e180]Google Scholar
  2. 2.
    Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621CrossRefPubMedGoogle Scholar
  3. 3.
    Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494–502. Errata. N Engl J Med 345(1506):1716Google Scholar
  4. 4.
    Steinhubl SR, Berger PB, Mann JT III et al (2003) Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized trial. JAMA 2002; 288:2411–2420 [Erratum, JAMA. 289:987]Google Scholar
  5. 5.
    Angiolillo DJ, Alfonso F (2007) Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost 98:707–709PubMedGoogle Scholar
  6. 6.
    Bonello L, Camoin-Jau L, Arques S et al (2008) Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51:1404–1411CrossRefPubMedGoogle Scholar
  7. 7.
    Gurbel PA, Becker RC, Mann KG et al (2007) Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50:1822–1834CrossRefPubMedGoogle Scholar
  8. 8.
    Brandt JT, Close SL, Iturria SJ et al (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429–2436CrossRefPubMedGoogle Scholar
  9. 9.
    Dorsam RT, Kunapuli SP (2004) Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113:340–345PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Fontana P, Dupont A, Gandrille S et al (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989–995CrossRefPubMedGoogle Scholar
  11. 11.
    Giusti B, Gori AM, Marcucci R et al (2007) Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 17:1057–1064CrossRefPubMedGoogle Scholar
  12. 12.
    Hulot JS, Bura A, Villard E et al (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244–2247CrossRefPubMedGoogle Scholar
  13. 13.
    Sim SC, Risinger C, Dahl ML et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113CrossRefPubMedGoogle Scholar
  14. 14.
    Suh JW, Koo BK, Zhang SY et al (2006) Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174:1715–1722 [Erratum, CMAJ. 175:e64]Google Scholar
  15. 15.
    Taubert D, von Beckerath N, Grimberg G et al (2006) Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80:486–501CrossRefPubMedGoogle Scholar
  16. 16.
    Tempening C (2010) Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol 4:117–128CrossRefGoogle Scholar
  17. 17.
    Trenk D, Hochholzer W, Fromm MF et al (2008) Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925–1934CrossRefPubMedGoogle Scholar
  18. 18.
    Adler G, Łoniewska B, Parczewski M et al (2009) Frequency of common CYP3A5 gene variants in healthy Polish newborn infants. Pharmacol Rep 61:947–951CrossRefPubMedGoogle Scholar
  19. 19.
    Ameyaw MM, Regateiro F, Li T et al (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 significantly influenced by ethnicity. Pharmacogenetics 11:217–221CrossRefPubMedGoogle Scholar
  20. 20.
    Balram C, Sharma A, Sivathasan C et al (2003) Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol 56:78–83PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Dandara C, Lombard Z, Du Plooy I et al (2011) Genetic variants in CYP (-1 A2, -2C9. -2C19, 3A4, and 3A5), VKORC1 and ABCB1 genes in Black South African population: a window into diversity. Pharmacogenomics 12:1663–1670CrossRefPubMedGoogle Scholar
  22. 22.
    Dudarewicz M, Baranska M, Rychlik-Sych M et al (2012) C3435T polymorphisms of the ABCB1/MDR1 gene encoding P-glycoprotein in patients with inflammatory bowel disease in a Polish population. Pharmacol Report 64:343–350CrossRefGoogle Scholar
  23. 23.
    Fontana P, Senouf D, Mach F (2008) Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 121:463–468CrossRefPubMedGoogle Scholar
  24. 24.
    Lim JS, Chen XA, Singh O et al (2011) Impact of CYP2D6, CYP3A5, CY2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol 71:737–750PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Shin DJ, Kwon J, Park AR et al (2012) Association of CYP2C19*2 and *3 genetic Variants with essential hypertension in Koreans. Yonsei Med J 53:1113–1119. doi: 10.3349/ymj.2012.53.6.1113 PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Liu YP, Hao PP, Zhang MX et al (2011) Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an update meta-analysis. Thromb Res 128:593–594Google Scholar
  27. 27.
    Kassimis G, Davlouros P, Xanthopoulou I et al (2012) CYP2C19*2 and other variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thromb Res 129:441–446Google Scholar
  28. 28.
    Cuisset T, Frere C, Quilici J et al (2007) Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb Res 120:893–899CrossRefPubMedGoogle Scholar
  29. 29.
    Lee SJ, Sun IS, Jung EJ et al (2011) Identification of P2Y12 single-nucleotide polymorphisms and their influences on the variation in ADP-induced platelet aggregation. Thromb Res 127:220–227CrossRefPubMedGoogle Scholar
  30. 30.
    Lahiri DK, Numberger JI Jr (1991) A rapid non-enzymatic method for the preparation HMW DNA from blood for RFLP studies. Nucleic Acids Res 19:5444PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Santos PC, Soares RA, Santos DB et al (2011) CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet 12:13PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Salazar-Flores J, Torres-Reyes LA, Martinez-Cortes G et al (2012) Distribution of CYP2D6 and CYP2C19 polymorphisms associated with por metabolizer phenotype in five Amerindian groups and western mestizos from Mexico. Genet Test Mol Biomarks 16:1098–1104. doi: 10.1089/gtmb.2012.0055 CrossRefGoogle Scholar
  33. 33.
    Kurose K, Sugiyama E, Saito Y (2012) Population differences in major functional polymorphisms of pharmakinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical Trials for novel drug development. Drug Metab Pharmacokinet 27:9–54CrossRefPubMedGoogle Scholar
  34. 34.
  35. 35.
  36. 36.
  37. 37.
    Park SY, Kang YS, Jeong MS et al (2008) Frequencies of CYP3A5 genotypes and haplotypes in a Korean population. J Clin Pharm Ther 33:61–65CrossRefPubMedGoogle Scholar
  38. 38.
  39. 39.
    Feng WX, Liu F, Gu Y et al (2012) Functional polymorphisms in CYP2C19 & CYP3A5 genes associated with decreased susceptibility for paediatric tuberculosis. Indian J Med Res 135:642–649PubMedCentralPubMedGoogle Scholar
  40. 40.
    Ellis KJ, Stouffer GA, McLeod HL et al (2009) Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 11:1799–1817. doi: 10.2217/pgs.09.143 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Gilberto Vargas-Alarcón
    • 1
  • Julián Ramírez-Bello
    • 2
  • Aurora de la Peña
    • 3
    • 4
  • Beatriz Calderón-Cruz
    • 4
  • Marco Antonio Peña-Duque
    • 5
  • Marco Antonio Martínez-Ríos
    • 5
  • Silvestre Ramírez-Fuentes
    • 1
  • Oscar Pérez-Méndez
    • 1
  • José Manuel Fragoso
    • 1
  1. 1.Department of Molecular BiologyInstituto Nacional de Cardiología Ignacio ChávezMexico CityMexico
  2. 2.Histocompatibility Laboratory, Unit of ResearchHospital Juárez de MexicoMexico CityMexico
  3. 3.Departament of Pharmacology, Faculty of MedicineUniversidad Nacional Autónoma de MéxicoMexico CityMexico
  4. 4.Thrombosis and Fribrinolysis LaboratoryInstituto Nacional de Cardiología Ignacio ChávezMexico CityMexico
  5. 5.Interventional CardiologyInstituto Nacional de Cardiología Ignacio ChávezMexico CityMexico

Personalised recommendations